Skip to main content
TipRanks
Go Ultimate75% OFF

Eupraxia Pharmaceuticals (EPRX) Stock Price & Analysis

48 Followers

EPRX Stock Chart & Stats

$6.21-$0.41(-6.19%)
At close: 4:00 PM EST
$6$7$8$9Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$6.11 - $6.69
52-Week Range
$5.63 - $9.32
Previous Close
$6.62
Volume
N/A
Average Volume (3M)
675.19K
Market Cap
$419.19M
Enterprise Value
$745.29M
Total Cash (Recent Filing)
$125.61M
Total Debt (Recent Filing)
$3.40M
Price to Earnings (P/E)
―
Beta
1.26
Next Earnings
Mar 30, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Drug-delivery Platform

DiffuSphere gives Eupraxia a defined technology platform for developing locally delivered, extended-release medicines. By targeting controlled release at the disease site and reduced systemic exposure, the platform could support differentiated products across multiple indications if clinical development succeeds.

Low Financial Leverage

The relatively small debt burden provides greater financial flexibility than a highly leveraged structure would. Lower leverage can reduce financing pressure and preserve room to fund clinical programs, absorb development variability, and allocate capital while the company remains pre-commercial.

Expanded Capitalization

The substantial expansion in assets and capitalization indicates that Eupraxia has materially strengthened its resource base since 2023. This supports continued investment in research, trials, and regulatory preparation, although the durability of that support depends on controlling ongoing cash use.

Bears Say

No Commercial Revenue

The absence of revenue means Eupraxia has not yet demonstrated commercial product demand or an operating revenue engine. Until a program reaches commercialization, the company remains dependent on financing and clinical progress rather than internally generated sales to support its activities.

Widening Operating Losses

Losses have expanded across the reported periods, showing that the current development model is consuming more resources without offsetting revenue. Persistent loss growth can weaken shareholder returns and increase the funding required before clinical programs produce commercial earnings.

Heavy Cash Burn

Sustained negative operating and free cash flow creates an ongoing need to finance research and clinical execution externally. The increase in annual burn through 2025 raises the risk that available capital will support a shorter development runway or require additional funding before commercialization.

Eupraxia Pharmaceuticals News

EPRX FAQ

What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was $5.63 and its highest was $9.32 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Eupraxia Pharmaceuticals’s market cap is $419.19M.
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s next earnings report is estimated for Mar 30, 2027 (not yet confirmed), which is in 131 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Eupraxia Pharmaceuticals released its earnings results on Nov 09, 2026. The company reported -$0.226 earnings per share for the quarter, beating the consensus estimate of -$0.262 by $0.036.
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate is -0.28.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 67,268,250 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Eupraxia Pharmaceuticals reported an EPS of -$0.226 in its last earnings report, beating expectations of -$0.262. Following the earnings report the stock price went up 2.83%.
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in EPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology